Regional Emergence of Candida auris in Chicago and Lessons Learned From Intensive Follow-up at 1 Ventilator-Capable Skilled Nursing Facility.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
31 12 2020
Historique:
received: 13 01 2020
accepted: 13 04 2020
pubmed: 16 4 2020
medline: 29 4 2021
entrez: 16 4 2020
Statut: ppublish

Résumé

Since the identification of the first 2 Candida auris cases in Chicago, Illinois, in 2016, ongoing spread has been documented in the Chicago area. We describe C. auris emergence in high-acuity, long-term healthcare facilities and present a case study of public health response to C. auris and carbapenemase-producing organisms (CPOs) at one ventilator-capable skilled nursing facility (vSNF-A). We performed point prevalence surveys (PPSs) to identify patients colonized with C. auris and infection-control (IC) assessments and provided ongoing support for IC improvements in Illinois acute- and long-term care facilities during August 2016-December 2018. During 2018, we initiated a focused effort at vSNF-A and conducted 7 C. auris PPSs; during 4 PPSs, we also performed CPO screening and environmental sampling. During August 2016-December 2018 in Illinois, 490 individuals were found to be colonized or infected with C. auris. PPSs identified the highest prevalence of C. auris colonization in vSNF settings (prevalence, 23-71%). IC assessments in multiple vSNFs identified common challenges in core IC practices. Repeat PPSs at vSNF-A in 2018 identified increasing C. auris prevalence from 43% to 71%. Most residents screened during multiple PPSs remained persistently colonized with C. auris. Among 191 environmental samples collected, 39% were positive for C. auris, including samples from bedrails, windowsills, and shared patient-care items. High burden in vSNFs along with persistent colonization of residents and environmental contamination point to the need for prioritizing IC interventions to control the spread of C. auris and CPOs.

Sections du résumé

BACKGROUND
Since the identification of the first 2 Candida auris cases in Chicago, Illinois, in 2016, ongoing spread has been documented in the Chicago area. We describe C. auris emergence in high-acuity, long-term healthcare facilities and present a case study of public health response to C. auris and carbapenemase-producing organisms (CPOs) at one ventilator-capable skilled nursing facility (vSNF-A).
METHODS
We performed point prevalence surveys (PPSs) to identify patients colonized with C. auris and infection-control (IC) assessments and provided ongoing support for IC improvements in Illinois acute- and long-term care facilities during August 2016-December 2018. During 2018, we initiated a focused effort at vSNF-A and conducted 7 C. auris PPSs; during 4 PPSs, we also performed CPO screening and environmental sampling.
RESULTS
During August 2016-December 2018 in Illinois, 490 individuals were found to be colonized or infected with C. auris. PPSs identified the highest prevalence of C. auris colonization in vSNF settings (prevalence, 23-71%). IC assessments in multiple vSNFs identified common challenges in core IC practices. Repeat PPSs at vSNF-A in 2018 identified increasing C. auris prevalence from 43% to 71%. Most residents screened during multiple PPSs remained persistently colonized with C. auris. Among 191 environmental samples collected, 39% were positive for C. auris, including samples from bedrails, windowsills, and shared patient-care items.
CONCLUSIONS
High burden in vSNFs along with persistent colonization of residents and environmental contamination point to the need for prioritizing IC interventions to control the spread of C. auris and CPOs.

Identifiants

pubmed: 32291441
pii: 5820113
doi: 10.1093/cid/ciaa435
pmc: PMC8376188
mid: NIHMS1732247
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e718-e725

Subventions

Organisme : NCEZID CDC HHS
ID : U50 CK000367
Pays : United States
Organisme : NCEZID CDC HHS
ID : U54 CK000481
Pays : United States
Organisme : NCEZID CDC HHS
ID : U54 CK000607
Pays : United States
Organisme : ACL HHS
ID : U54CK000481
Pays : United States

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

J Am Coll Surg. 2008 Aug;207(2):233-9
pubmed: 18656052
J Am Geriatr Soc. 2008 Jul;56(7):1276-80
pubmed: 18557965
Antimicrob Resist Infect Control. 2016 Oct 19;5:35
pubmed: 27777756
J Clin Microbiol. 2018 Jan 24;56(2):
pubmed: 29187562
J Am Med Dir Assoc. 2012 Jul;13(6):568.e1-13
pubmed: 22575772
Infect Control Hosp Epidemiol. 2010 Nov;31(11):1160-9
pubmed: 20874503
J Clin Microbiol. 2012 May;50(5):1698-703
pubmed: 22378900
J Clin Microbiol. 2017 Oct;55(10):2996-3005
pubmed: 28747370
MMWR Morb Mortal Wkly Rep. 2016 Nov 11;65(44):1234-1237
pubmed: 27832049
Clin Infect Dis. 2015 Apr 15;60(8):1153-61
pubmed: 25537877
Clin Infect Dis. 2011 Sep;53(6):532-40
pubmed: 21865189
Emerg Infect Dis. 2018 Oct;24(10):1816-1824
pubmed: 30226155
Mycoses. 2019 Jun;62(6):513-518
pubmed: 30801778
Infect Control Hosp Epidemiol. 2017 Sep;38(9):1107-1109
pubmed: 28693657
Eur J Clin Microbiol Infect Dis. 2010 Apr;29(4):391-7
pubmed: 20111880
Emerg Infect Dis. 2015 Oct;21(10):1725-32
pubmed: 26402744
MMWR Morb Mortal Wkly Rep. 2017 May 19;66(19):514-515
pubmed: 28520710
Infect Control Hosp Epidemiol. 2017 Oct;38(10):1240-1243
pubmed: 28793937
Clin Infect Dis. 2018 Jan 6;66(2):306-311
pubmed: 29020224

Auteurs

Massimo Pacilli (M)

Communicable Disease Program, Chicago Department of Public Health, Chicago, Illinois, USA.

Janna L Kerins (JL)

Communicable Disease Program, Chicago Department of Public Health, Chicago, Illinois, USA.

Whitney J Clegg (WJ)

Communicable Disease Program, Chicago Department of Public Health, Chicago, Illinois, USA.

Kelly A Walblay (KA)

Communicable Disease Program, Chicago Department of Public Health, Chicago, Illinois, USA.

Hira Adil (H)

Communicable Disease Program, Chicago Department of Public Health, Chicago, Illinois, USA.

Sarah K Kemble (SK)

Communicable Disease Program, Chicago Department of Public Health, Chicago, Illinois, USA.

Shannon Xydis (S)

Communicable Disease Program, Chicago Department of Public Health, Chicago, Illinois, USA.

Tristan D McPherson (TD)

Communicable Disease Program, Chicago Department of Public Health, Chicago, Illinois, USA.
Epidemic Intelligence Service, Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, USA.

Michael Y Lin (MY)

Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.

Mary K Hayden (MK)

Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.

Mary Carl Froilan (MC)

Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.

Elizabeth Soda (E)

Illinois Department of Public Health, Chicago, Illinois, USA.
Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, USA.

Angela S Tang (AS)

Illinois Department of Public Health, Chicago, Illinois, USA.

Ann Valley (A)

Wisconsin State Laboratory of Hygiene, Madison, Wisconsin, USA.

Kaitlin Forsberg (K)

Mycotic Diseases Branch, Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, USA.

Paige Gable (P)

Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, USA.

Heather Moulton-Meissner (H)

Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, USA.

D Joseph Sexton (DJ)

Mycotic Diseases Branch, Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, USA.

Kara M Jacobs Slifka (KM)

Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, USA.

Snigdha Vallabhaneni (S)

Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, USA.

Maroya Spalding Walters (MS)

Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, USA.

Stephanie R Black (SR)

Communicable Disease Program, Chicago Department of Public Health, Chicago, Illinois, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH